- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01921933
The Optiflow Patency and Maturation Study (OPEN)
The "OPEN" Study Optiflow PatEncy and MaturatioN
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The investigation is designed as a multi-center, prospective, single-arm, clinical study of the Optiflow performance and safety in a maximum of 180 subjects which includes one (1) roll-in subjects per investigator (maximum of 36 roll-in subjects). Subjects will be followed at 14 days post-procedure, 42 days post-procedure, and 90 days post-procedures.
Results will be compared to a pre-established performance goal.
Up to fifteen (15) investigational sites will participate in the investigational study.
The primary performance endpoint is the overall maturation percentage rate at 90 days. Maturation is defined as an access site which achieves a diameter of greater or equal to 4 mm and blood flow greater or equal t0 500 mL/min as measured via duplex ultrasound.
The primary safety endpoint is a composite endpoint of serious adverse events known to be associated with arteriovenous fistula anastomosis surgical procedures through 90 days.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ohio
-
Cincinnati, Ohio, United States, 45267-0585
- University of Cincinnati - Division of Nephrology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or non-pregnant female (verified with a urine/blood pregnancy test, for women of reproductive age).
- Life expectancy of at least one year, per the investigator's opinion.
- Diagnosed with ESRD or chronic kidney disease requiring dialysis.
- Planned upper extremity autogenous arteriovenous fistula.
- Planned anastomosis is an end of vein to side of artery configuration.
- AVF target artery and vein inner diameters are greater or equal to 3.0 mm and less than or equal to 7.0 mm as determined by pre-operative ultrasound and confirmed intra-operatively.
- Patient is available and willing to return for follow-up visits during the duration of the study.
- Patient is able and willing to follow a daily aspirin and/or other anticoagulation/antiplatelet regimen not including warfarin (see exclusion criteria).
- Patient, or their legal representative, is willing and able to provide informed consent.
Exclusion Criteria:
- Known bleeding diathesis or coagulation disorder.
- Documented or suspected central venous stenosis.
- Uncontrolled hypotension with systolic blood pressures < 100 mg Hg at the time of screening.
- Peripheral white blood cell count < 1.5 K/mm3 or platelet count < 75,000 cells/mm3.
- Body Mass Index (BMI) > 42.
- Transposition of the access vein is anticipated within the 90 day follow-up interval.
- Receiving anticoagulant therapy for non-cardiac indications.
- Evidence or history of an active or suspected infection within one month of screening.
- Scheduled kidney transplant within six months of enrollment.
- History of ≥ 2 AVF and/or synthetic access graft failures.
- History of steal syndrome from a previous hemodialysis vascular access which required intervention or abandonment.
- Current participation in another clinical trial (excluding retrospective studies or studies not requiring a consent form).
- Anticipated surgery requiring general anesthesia during the course of follow-up.
- A history of substance abuse.
- Anticipated to be non-compliant with medical care or study requirements based on investigator judgment.
- Need for immunosuppressive therapy at a dose greater than the equivalent of prednisone 10 mg per day.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Optiflow
The Optiflow device will be implanted in the upper extremity of Adult end-stage renal disease (ESRD) patients requiring creation of an upper extremity autogenous arteriovenous fistula for dialysis access.
|
The Optiflow device will be implanted in the upper extremity of Adult end-stage renal disease (ESRD) patients requiring creation of an upper extremity autogenous arteriovenous fistula for dialysis access.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fistula Maturation
Time Frame: 90 days
|
The primary performance endpoint is the maturation percentage rate at 90 days.
Maturation is defined as an access site intended for dialysis needle cannulation which achieves a diameter of greater or equal to 4 mm and blood flow greater or equal to 500 mL/min as measured via duplex ultrasound.
|
90 days
|
Serious Adverse Events Associated with Arteriovenous Fistula Creation
Time Frame: 90 days
|
The primary safety endpoint is a composite endpoint of serious adverse events known to be associated with arteriovenous fistula anastomosis surgical procedures through 90 days.
All patients will be followed for safety for the duration of the study.
|
90 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Technical success
Time Frame: 1 day
|
Technical success rate: An access site that demonstrates physical exam patency through hospital discharge.
|
1 day
|
Assisted Maturation
Time Frame: 90 days
|
Assisted maturation rate: An access site which achieves or maintains maturation following intervening manipulations (surgical or endovascular) designed to promote or reestablish maturation.
|
90 days
|
Unassisted Maturation
Time Frame: 90 days
|
Unassisted fistula maturation rate: An access site that achieves and maintains maturation without any surgical or endovascular intervention designed to promote or reestablish Maturation.
|
90 days
|
Assisted Patency
Time Frame: 90 days
|
Assisted patency rate: An access site which is patent after intervening manipulations (surgical or endovascular) intended to promote or reestablish patency.
|
90 days
|
Unassisted Patency
Time Frame: 90 days
|
Unassisted patency rate: An access site that maintains patency without any surgical or endovascular intervention designed to maintain or reestablish blood flow in the access site.
|
90 days
|
Intervention Rate
Time Frame: 90 days
|
Intervention rate: The number of occurrences that a subject's access site is surgically or endovascularly operated on to maintain or reestablish blood flow in the access site.
|
90 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to first cannulation
Time Frame: Up to 90 days
|
Elapsed time to first use of access site.
|
Up to 90 days
|
Ultrasound flow
Time Frame: 90 days
|
Flow rate of blood through outflow vein
|
90 days
|
Time To Access Site Abandonment
Time Frame: Up to 90 days
|
Elapsed time to abandonment of the access site.
|
Up to 90 days
|
Access Site Related Adverse Events
Time Frame: 90 days
|
The number of access related adverse events per subject
|
90 days
|
Number of Access Site Related Hospitalizations
Time Frame: 90 days
|
The number of access site related hospitalizations per subject.
|
90 days
|
Catheter Utilization
Time Frame: 90 days
|
Total number of days a catheter was used before access site maturation per subject.
|
90 days
|
Total Adverse Events
Time Frame: 90 days
|
Total number of adverse events
|
90 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BCS_TP1070
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on End-stage Renal Disease
-
Outset MedicalCompletedAcute Kidney Injury | End Stage Renal Disease (ESRD) | End Stage Renal Disease on DialysisUnited States
-
University of Illinois at ChicagoWithdrawnObesity | End-Stage Renal Disease | Renal Disease, End-Stage | Renal Failure, End-StageUnited States
-
Xinhua Hospital, Shanghai Jiao Tong University...Changhai Hospital; Shanghai Zhongshan Hospital; RenJi Hospital; Ruijin Hospital; Shanghai... and other collaboratorsCompleted
-
Clinical Research Center for End Stage Renal Disease...Kyungpook National University Hospital; Medical Research Collaborating Center... and other collaboratorsActive, not recruitingEnd-Stage Renal DiseaseKorea, Republic of
-
Medtronic - MITGCompletedEnd-stage Renal DiseaseGermany
-
China Medical University HospitalUnknown
-
Guangdong Provincial Hospital of Traditional Chinese...Ministry of Science and Technology of the People´s Republic of ChinaUnknown
-
University of California, San FranciscoCompletedEnd-stage Renal DiseaseUnited States
-
Mark A. LumleyHenry Ford Health SystemCompleted
-
Vanderbilt University Medical CenterNational Center for Complementary and Integrative Health (NCCIH)CompletedEnd-stage Renal DiseaseUnited States
Clinical Trials on Optiflow
-
Cliniques universitaires Saint-Luc- Université...Completed
-
NHS Greater Glasgow and ClydeFisher and Paykel HealthcareUnknown
-
University Health Network, TorontoUnknown
-
University Hospital, GhentCompleted
-
Nantes University HospitalCompletedHypoxemic Acute Respiratory FailureFrance
-
University Hospital, BordeauxCompleted
-
Virginia Commonwealth UniversityCompletedCystic FibrosisUnited States
-
Nantes University HospitalCompletedNeed for Intubation, No Severe HypoxemiaFrance
-
University Hospital, BordeauxCompleted
-
Ajou University School of MedicineNot yet recruitingInduction of General Anesthesia